4//SEC Filing
Korenberg Matthew E 4
Accession 0002001011-24-000082
CIK 0000886163other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 7:55 PM ET
Size
23.4 KB
Accession
0002001011-24-000082
Insider Transaction Report
Form 4
Korenberg Matthew E
VP, Finance and CFO
Transactions
- Tax Payment
Common Stock
2024-09-16$105.00/sh−1,938$203,490→ 52,070 total - Exercise/Conversion
Common Stock
2024-09-16$49.99/sh+671$33,543→ 50,987 total - Exercise/Conversion
Common Stock
2024-09-16$60.94/sh+3,340$203,540→ 54,008 total - Tax Payment
Common Stock
2024-09-16$105.00/sh−472$49,560→ 50,316 total - Exercise/Conversion
Common Stock
2024-09-16$58.49/sh+849$49,658→ 50,788 total - Tax Payment
Common Stock
2024-09-16$105.00/sh−319$33,495→ 50,668 total - Exercise/Conversion
Common Stock
2024-09-16$55.75/sh+914$50,956→ 50,424 total - Tax Payment
Common Stock
2024-09-16$105.00/sh−485$50,925→ 49,939 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-16−671→ 5,377 totalExercise: $49.99Exp: 2026-02-11→ Common Stock (671 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-16−914→ 25,949 totalExercise: $55.75Exp: 2030-02-13→ Common Stock (914 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-16−849→ 12,452 totalExercise: $58.49Exp: 2027-02-24→ Common Stock (849 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-16−3,340→ 18,500 totalExercise: $60.94Exp: 2025-08-06→ Common Stock (3,340 underlying)
Footnotes (4)
- [F1]This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
- [F2]This Option was previously reported as a Grant of 30,750 shares on February 13, 2020, at an exercise price of $95.68 per share , but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on February 13, 2024.
- [F3]This Option was previously reported as a Grant of 15,225 shares on February 24, 2017, which vested in full on February 24, 2021, at an exercise price of $100.38 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
- [F4]This Option was previously reported as a Grant of 25,000 shares on August 06, 2015, which vested in full on August 06, 2019, at an exercise price of $104.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001649903
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 7:55 PM ET
- Size
- 23.4 KB